臨床検査65巻5号

2021年05月発行

今月の特集 薬剤耐性（AMR）対策の現状と今後

薬剤耐性菌感染症に対する治療薬の開発の動向

著者： 石井良和¹

所属機関： ¹東邦大学医学部微生物・感染症学講座

ページ範囲：P.541 - P.547

Point

●治療薬の開発は薬剤耐性グラム陰性菌を中心に進められている．

●既存の抗菌薬の改良やドラッグリポジショニング，新規標的の抗菌薬，バクテリオファージ，病原性改善薬，抗体，抗体やキャリア物質と抗菌性物質コンジュゲートなどの開発が試みられている．

●既存の抗菌薬の改良によるいくつかの感染症治療薬は，すでに欧米で実用化されている．

●それ以外の感染症治療薬は，現在知られている抗菌薬耐性機序によって耐性が獲得されにくいものが多く，今後の展開に興味がもたれている．

参考文献

1）Ito A, Sato T, Ota M, et al：In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother　62：e01454-17，2017

2）Yahav D, Giske CG, Grāmatniece A, et al：New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev　34：e00115-20，2020

3）Kitadokoro K, Tanaka M, Hikima T, et al：Crystal structure of pathogenic Staphylococcus aureus lipase complex with the anti-obesity drug orlistat. Sci Rep　10：5469，2020

4）Zipperer A, Konnerth MC, Laux C, et al：Human commensals producing a novel antibiotic impair pathogen colonization. Nature　535：511-516，2016

5）Chu J, Vila-Farres X, Inoyama D, et al：Discovery of MRSA active antibiotics using primary sequence from the human microbiome. Nat Chem Biol　12：1004-1006，2016

6）Adnan M, Patel M, Deshpande S, et al：Effect of Adiantum philippense Extract on Biofilm Formation, Adhesion With Its Antibacterial Activities Against Foodborne Pathogens, and Characterization of Bioactive Metabolites: An in vitro-in silico Approach. Front Microbiol　11：823，2020

7）Ali SO, Yu XQ, Robbie GJ, et al：Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect　25：629. e1-629. e6，2019

8）Zurawski DV, McLendon MK：Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens. Antibiotics （Basel）　9：155，2020

9）Liu R, Miller PA, Vakulenko SB, et al：A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic. J Med Chem　61：3845-3854，2018

10）Neumann W, Sassone-Corsi M, Raffatellu M, et al：Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin-Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity. J Am Chem Soc　140：5193-5201，2018

11）Lehar SM, Pillow T, Xu M, et al：Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature　527：323-328，2015

12）Huang YY, Wintner A, Seed PC, et al：Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model. Sci Rep　8：7257，2018

13）Recacha E, Machuca J, Díaz de Alba P, et al：Quinolone Resistance Reversion by Targeting the SOS Response. mBio　8：e00971-17，2017

14）Jault P, Leclerc T, Jennes S, et al：Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis　19：35-45，2019

15）Wienhold SM, Lienau J, Witzenrath M：Towards Inhaled Phage Therapy in Western Europe. Viruses　11：295，2019

16）Díez-Martínez R, De Paz HD, García-Fernández E, et al：A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother　70：1763-1773，2015

17）Gordillo Altamirano FL, Barr JJ：Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev　32：e00066-18，2019

18）Raj G, Priyadarshini R, Murugesan S, et al：Monoclonal antibodies against infectious microbes: so long and too little! Infect Disord Drug Targets, 2020, in press

19）Negash KH, Norris JKS, Hodgkinson JT：Siderophore-Antibiotic Conjugate Design: New Drugs for Bad Bugs? Molecules　24：3314，2019